Латвія - латвійська - Zāļu valsts aģentūra

egis pharmaceuticals plc, hungary - paliperidons - ilgstošās darbības suspensija injekcijām pilnšļircē - 50 mg

Латвія - латвійська - Zāļu valsts aģentūra

egis pharmaceuticals plc, hungary - paliperidons - ilgstošās darbības suspensija injekcijām pilnšļircē - 75 mg

Латвія - латвійська - Zāļu valsts aģentūra

egis pharmaceuticals plc, hungary - paliperidons - ilgstošās darbības suspensija injekcijām pilnšļircē - 100 mg

Латвія - латвійська - Zāļu valsts aģentūra

egis pharmaceuticals plc, hungary - paliperidons - ilgstošās darbības suspensija injekcijām pilnšļircē - 150 mg

Латвія - латвійська - Zāļu valsts aģentūra

zaklady farmaceutyczne polpharma s.a., poland - metronidazols - tablete - 250 mg

Європейський Союз - латвійська - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - cobicistat, atazanavir - hiv infekcijas - pretvīrusu līdzekļi sistēmiskai lietošanai - evotaz is indicated in combination with other antiretroviral medicinal products for the treatment of hiv-1 infected adults and adolescents (aged 12 years and older weighing at least 35 kg) without known mutations associated with resistance to atazanavir (see sections 4. 4 un 5.

Європейський Союз - латвійська - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - belatacept - graft rejection; kidney transplantation - imūnsupresanti - nulojix, in combination with corticosteroids and a mycophenolic acid (mpa), is indicated for prophylaxis of graft rejection in adult recipients of a renal transplant.

Європейський Союз - латвійська - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - idecabtagene vicleucel - multiple myeloma; neoplasms; cancer; neoplasms, plasma cell; hemostatic disorders; vascular diseases; cardiovascular diseases; paraproteinemias; blood protein disorders; hematologic diseases; hemic and lymphatic diseases; hemorrhagic disorders; infectious mononucleosis; lymphoproliferative disorders; immunoproliferative disorders; immune system diseases - antineoplastiski līdzekļi - abecma is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti cd38 antibody and have demonstrated disease progression on the last therapy.

Європейський Союз - латвійська - EMA (European Medicines Agency)

leo pharma a/s - tacrolimus - dermatīts, atopisks - citi dermatoloģiski preparāti - flare treatmentadults and adolescents (16 years of age and above)treatment of moderate to severe atopic dermatitis in adults who are not adequately responsive to or are intolerant of conventional therapies such as topical corticosteroids. children (two years of age and above)treatment of moderate to severe atopic dermatitis in children (two years of age and above) who failed to respond adequately to conventional therapies such as topical corticosteroids. maintenance treatmentmaintenance treatment of moderate to severe atopic dermatitis for the prevention of flares and the prolongation of flare-free intervals in patients experiencing a high frequency of disease exacerbations (i. sastopamas četras vai vairāk reizes gadā), kas ir bijusi pirmā atbilde, lai maksimāli sešas nedēļas ārstēšanai divreiz dienā takrolīma ziede (bojājumi noskaidroti, gandrīz noskaidroti vai daļēji ietekmē).

Латвія - латвійська - Zāļu valsts aģentūra

bristol-myers squibb kft, hungary - hidroksikarbamīds - kapsula, cietā - 500 mg